Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
186 Leser
Artikel bewerten:
(1)

EVIO, Inc. Announces William Waldrop as President and Chief Executive Officer

HENDERSON, NV / ACCESSWIRE / March 31, 2022 / EVIO, Inc. (OTC:EVIO) announced today that William H. Waldrop has been named as President and Chief Executive Officer.

Mr. Waldrop served as EVIO's Chief Executive Officer for six years building a nationwide testing company. He took time away from the company to focus on his health in late 2020. Also during this time he founded Tiderock Companies (TDRK) a real estate advisory services and development company in which he still serves as a Director and Chief Financial Officer.

Ms. Glauser has assumed the role of Chief Operating Officer, and will focus on blockchain technologies, leveraging EVIO's customer relationships and expertise while evaluating new areas for EVIO to diversify. Mr. Waldrop, expressed his support for Ms. Glauser, "Lori has done a tremendous job managing the business during a very difficult time for the Company. She continued the efforts to prepare EVIO for future growth opportunities, identifying and executing strategic partnerships, while eliminating millions of dollars of debt from the balance sheet."

Mr. Waldrop continued to comment, "I am returning to EVIO with a clearer perspective, open eyes, and an open mind. There is still a lot of work to do to complete the turn-around, at the same time we have an abundance of opportunity as we evaluate options to diversify our holdings and more importantly focus on increasing shareholder value. Furthermore, the company has no plans to perform a reverse stock split in the foreseeable future. We feel the current share price provides ample opportunity for shareholders to benefit from the work efforts that are underway. The only downside at this price per share is that any debt conversion or share issuance for cash appears to have dramatic impact on the number of outstanding shares while having marginal impact on the overall market value." Ms. Glauser adds "I welcome William back to lead EVIO into the next phase of its growth."

About EVIO
EVIO, Inc. ("EVIO") is a diversified holding company. Current operations include pharmaceutical, environmental, stability and analytical testing in the US and Canada. EVIO is currently evaluating opportunities to further diversify its holdings.

For more information, visit www.eviolabs.com

Safe Harbor Statement

Any statements in this press release that are not statements of historical fact may be considered forward-looking statements pertaining to anticipated or projected plans, performance, and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only, and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, the Company's ability to complete product testing and launch product commercially, the acceptance of product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in Company reports available at www.eviolabs.com.

For more information:

EVIO Inc.
William Waldrop, CEO
Email: info@evioinc.com
Phone (702)748-9944

SOURCE: EVIO, Inc.



View source version on accesswire.com:
https://www.accesswire.com/695504/EVIO-Inc-Announces-William-Waldrop-as-President-and-Chief-Executive-Officer

© 2022 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.